FDA Approves First mRNA Flu Vaccine in the U.S.

Rubric: Health
Format: Special Report
Author: Sinisa Brkic (sb)

The U.S. Food and Drug Administration has approved Moderna’s MFLUSIVA for adults age 50 and older, making it the first seasonal influenza vaccine based on mRNA technology to receive approval in the United States. The decision extends the mRNA platform beyond COVID vaccination and into one of the world’s largest recurring vaccine markets, while important questions remain about real world performance, availability and its eventual role in U.S. vaccination policy.

A new chapter for mRNA vaccine technology

The approval of MFLUSIVA marks an important expansion of messenger RNA technology. The platform that became widely known during the COVID pandemic will now be used in the United States against seasonal influenza, a disease that requires vaccine formulations to be reassessed and produced year after year.

The distinction is important. MFLUSIVA is not the first mRNA vaccine approved by the FDA. It is the first mRNA vaccine approved in the United States specifically for the prevention of seasonal influenza, giving the technology a new commercial and public health application beyond COVID vaccination.

MFLUSIVA is designed to generate immune responses against influenza strains selected for the seasonal vaccine. Instead of producing the target antigen through conventional egg based or cell based manufacturing methods, the vaccine delivers messenger RNA instructions that enable cells to produce the relevant influenza proteins and stimulate an immune response.

That difference in manufacturing architecture is one reason the approval has significance beyond a single vaccine. Influenza remains a moving target, and the ability to update vaccine designs more rapidly has long been considered one of the potential advantages of mRNA technology.

The FDA granted different forms of approval by age

The regulatory decision is not identical across the entire approved population. Adults between 50 and 64 received traditional FDA approval, while people age 65 and older received approval through the accelerated approval pathway.

That distinction matters because the two regulatory routes are based on different evidentiary structures. Traditional approval relies on evidence demonstrating clinical benefit, while accelerated approval can permit earlier authorization based on a measure considered reasonably likely to predict benefit, subject to additional confirmatory requirements.

For adults age 65 and older, Moderna will therefore remain responsible for generating further evidence to confirm the anticipated clinical benefit. The vaccine is approved for this age group, but its regulatory status should not be presented as identical to the traditional approval granted to adults between 50 and 64.

The distinction is particularly relevant because older adults already have access to influenza vaccines specifically designed to produce stronger immune responses. MFLUSIVA enters a market in which high dose and adjuvanted vaccines are already established options for seniors.

What the 26.6 percent efficacy advantage actually means

One of the most important figures associated with the approval is a relative vaccine efficacy advantage of approximately 26.6 percent compared with a licensed standard influenza vaccine in the pivotal Phase 3 study.

That figure requires careful interpretation. It does not mean that MFLUSIVA provided an additional 26.6 percentage points of protection to everyone who received it. It describes the relative reduction in qualifying influenza cases compared with the standard vaccine used as the study comparator.

In the main analysis, about 2.0 percent of participants receiving the mRNA vaccine developed a qualifying laboratory confirmed influenza illness, compared with about 2.8 percent in the comparator group. The absolute difference between the two groups was therefore approximately 0.8 percentage points.

Both figures are relevant. The relative result indicates that fewer qualifying influenza cases occurred in the MFLUSIVA group, while the absolute numbers show the actual difference observed among participants during the study.

Confusing relative and absolute effects can significantly distort how vaccine performance is understood. A 26.6 percent relative advantage is a meaningful study result, but it is not equivalent to saying that another 26.6 percent of all vaccinated people were protected from influenza.

Older adults present a more complex comparison

The evidence for people age 65 and older requires additional context. Standard dose influenza vaccines are not the only products already available to this population. Enhanced vaccines, including high dose formulations, have been used specifically because immune responses generally weaken with age.

The FDA therefore evaluated additional immune response data comparing MFLUSIVA with an established high dose influenza vaccine. Those data supported the regulatory case for the mRNA vaccine, but immune response measurements and demonstrated prevention of influenza illness are not the same outcome.

This difference helps explain why accelerated approval was used for the older population. Laboratory measures can provide important evidence about whether a vaccine is likely to work, but confirmatory clinical evidence remains necessary when regulators rely on such measures as predictors of benefit.

The approval consequently establishes MFLUSIVA as a new option for adults 65 and older. It does not establish that the product has already demonstrated greater clinical effectiveness than every enhanced influenza vaccine currently available to seniors.

Short term reactions were more frequent

The safety profile also requires precise reporting. Participants receiving MFLUSIVA experienced expected short term vaccine reactions more frequently than participants receiving the standard vaccine used for comparison.

Pain at the injection site, fatigue, headache, muscle discomfort, fever and other systemic reactions were among the effects documented after vaccination. Most were mild or moderate and resolved within a relatively short period.

The difference in reactogenicity was nevertheless substantial. Local reactions were reported considerably more often among MFLUSIVA recipients than among participants receiving the comparator vaccine, and systemic reactions were also more frequent.

More intense temporary reactions were likewise observed more often in the mRNA vaccine group. That finding does not automatically translate into a serious safety problem, but it is an important part of the vaccine’s overall profile and should not be obscured by the efficacy results.

Serious adverse events require a different reading

Serious adverse events were much more similar between the two study groups than routine short term reactions. Overall rates were close, and the available study data did not show a broad imbalance in mortality between recipients of MFLUSIVA and the comparator vaccine.

Regulatory reviewers also examined numerical differences involving specific categories of serious events and deaths. Numerical imbalances in a clinical trial warrant examination, but they do not by themselves establish that a vaccine caused the events.

Determining causality requires consideration of timing, underlying medical conditions, expected background rates, biological plausibility and the totality of the evidence. The FDA concluded that the findings it reviewed did not establish the relevant events as vaccine related safety signals.

That assessment does not end safety monitoring. Clinical trials involving tens of thousands of participants can identify common and moderately uncommon adverse effects, but very rare events may only become detectable after a vaccine is used across much larger populations.

Postmarket surveillance will therefore be a central part of the next phase.

Why influenza is an important test for mRNA

Seasonal influenza presents a different technological challenge from COVID vaccination. Influenza viruses change continuously, and global health authorities must regularly determine which strains should be included in vaccines for the coming season.

Manufacturers then face a narrow production window. Vaccines must be formulated, produced, tested, distributed and delivered before influenza activity reaches its seasonal peak.

Traditional influenza vaccine production relies on several established technologies, including egg based, cell based and recombinant manufacturing. These methods have produced billions of vaccine doses over decades, but they also require production processes that can limit the speed and flexibility of reformulation.

Messenger RNA offers a different model. Once the relevant viral sequence has been selected, the vaccine can in principle be redesigned without reproducing the antigen through the same biological manufacturing processes used by conventional platforms.

That possibility has long been one of the strongest arguments for applying mRNA technology to influenza. A platform that can be updated more rapidly could potentially reduce the time between strain selection and final vaccine production.

Whether that theoretical advantage produces better protection in actual influenza seasons remains a separate question.

Approval does not prove permanent superiority

MFLUSIVA’s Phase 3 results provide evidence of improved performance over the standard vaccine used in the pivotal study. They do not establish that an mRNA flu vaccine will outperform conventional vaccines in every future season.

Influenza vaccine effectiveness can vary substantially depending on which strains circulate and how closely they match those selected for the vaccine. Viral evolution between strain selection and the peak of the influenza season can reduce protection regardless of the underlying manufacturing technology.

The central long term question is therefore not simply whether mRNA technology can produce an approved influenza vaccine. That question has now been answered.

The more important test is whether the platform can consistently improve protection, respond more effectively to changing strains or shorten production timelines enough to create a meaningful clinical advantage over established technologies.

Those conclusions will require data from multiple influenza seasons rather than a single regulatory cycle.

The vaccine is not approved for everyone

MFLUSIVA is approved for adults age 50 and older. The FDA decision does not authorize the vaccine for younger adults, adolescents or children.

That limitation is important because headlines describing the approval simply as a new mRNA flu vaccine can create the impression of broader eligibility than the current authorization permits. Age eligibility should remain explicit whenever the product is discussed.

FDA approval also does not determine the vaccine’s final position in U.S. immunization practice. Recommendations from the Centers for Disease Control and Prevention and its vaccination advisory process will influence how clinicians, pharmacies, insurers and patients ultimately use the product.

The question is especially significant for adults age 65 and older because other influenza vaccines already receive particular consideration for this population. Regulatory approval opens the market, but clinical recommendations will help determine MFLUSIVA’s actual place within it.

Availability and coverage remain crucial questions

The timing of the approval creates another practical issue. Influenza vaccine procurement and distribution planning often begins well before the start of the season, meaning a newly approved product may not immediately achieve broad national availability.

The extent to which MFLUSIVA will be supplied during the 2026/27 influenza season therefore remains a critical issue. Limited early distribution would make the approval scientifically and commercially significant while keeping its immediate public health impact relatively modest.

Pricing will also matter. The product will compete with established influenza vaccines produced at large scale, and its uptake will depend not only on clinical data but also on reimbursement, insurance coverage, pharmacy access and purchasing decisions by health systems.

For older Americans, Medicare coverage and final vaccination recommendations could be particularly important. Until those elements are fully established, regulatory approval should not be confused with universal access.

Moderna gains a broader strategic opportunity

For Moderna, the FDA decision carries significance well beyond seasonal influenza. The company built much of its commercial position around mRNA vaccination during the COVID pandemic and has been seeking to demonstrate that the same platform can support a broader portfolio of vaccines and medicines.

An approved influenza vaccine gives the company another recurring respiratory vaccine market and provides additional validation of its underlying technology. It may also strengthen the strategic case for future combination products targeting more than one respiratory virus in a single vaccination.

That possibility has considerable commercial appeal. If mRNA platforms can be efficiently adapted to multiple respiratory pathogens, manufacturers could eventually compete not only through individual vaccines but through combinations designed around seasonal vaccination programs.

The regulatory path for each product will remain independent, however. Approval of MFLUSIVA cannot be treated as automatic validation of other mRNA vaccines or combination candidates still under development.

The real test begins after approval

The FDA decision is a milestone, but approval is only the beginning of the more consequential phase. MFLUSIVA will now have to demonstrate its value outside controlled clinical trials, across changing influenza seasons and against competing vaccines with decades of production and safety experience.

Researchers and regulators will watch several questions closely. They will examine whether the vaccine maintains its relative efficacy advantage, whether rare safety signals emerge after wider use, whether the mRNA platform allows faster seasonal updates and how the product performs in older adults once confirmatory evidence becomes available.

Commercial performance will provide another measure. A technologically innovative vaccine has limited practical impact if physicians, pharmacies, insurers and patients see insufficient benefit to justify switching from established alternatives.

The significance of the FDA decision is therefore best understood with both ambition and restraint. MFLUSIVA proves that mRNA technology has moved into seasonal influenza vaccination in the United States. What it does not yet prove is whether that technological shift will fundamentally change how well influenza can be prevented.

That answer will come not from the approval letter itself, but from the seasons that follow.